Adm. direktør Anders Hinsby er meget tilfreds med de friske data fra selskabets første fase 3-studie fra september, som selskabet nu har analyseret i dybden.
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Få fuld adgang til vores kvalitetsjournalistik med et prøveabonnement.
Head of In vivo Pharmacology - Zealand Pharma
Project Manager CMC - Genmab
Head of Medicinal Chemistry - Zealand Pharma
Area Account Manager - Ethicon
Clinical and Post Market Surveillance Specialist - Ferrosan Medical Devices
Director, Device Development - Ascendis Pharma
Sr. Manager Clinical Quality Assurance - Ascendis Pharma
Regulatory Drug-Device Combination Product Lead – Zealand Pharma
Director, Business Development - Zealand Pharma
Project Manager CMC - Organic Chemist - Ascendis Pharma
IT QA Manager - Genmab
Senior Manager Drug Product – Ascendis Pharma
Compliance Project Manager - Genmab
Senior Director, Regulatory Affairs - Ascendis Pharma
QA Professional – Drug Substance and Analytical Testing
Area Account Manager – Depuy Synthes
Senior Manager Downstream Manufacturing - Ascendis Pharma
Director, Regulatory Affairs (Device) - Ascendis Pharma
